ADMA Overview

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Wall Street analysts forecast ADMA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADMA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ADMA Biologics Inc revenue for the last quarter amounts to 114.49M USD, decreased -0.27

ADMA Biologics Inc. EPS for the last quarter amounts to 0.19 USD, increased 72.73

ADMA Biologics Inc (ADMA) has 647 emplpoyees as of May 31 2026.

Today ADMA has the market capitalization of 1.85B USD.